Georgia Tech Research Corporation

Clark Atlanta University, Inc.

Shafiq A Khan

Adegboyega K Oyelere

Subhasish Tapadar

Silvia Caggia

The disclosure relates to novel compounds and methods of use of the compounds to maintain the Gα2 protein in its inactive GDP-bound state. The disclosure describes the knockdown or inhibition of Gα2 negatively regulated migration of breast and ovarian cancer cell lines. The novel compounds inhibit the migratory behavior of PC3, DU145 and E006AA prostate cancer cell lines. Specifically, the novel compounds block the activation of Gα2 in oxytocin-stimulated prostate cancer PC3 cells and inhibits the migratory capability of DU145 cells overexpressing constitutively active form of Gα2, under basal and EGF-stimulated conditions.

Growing community of inventors

Mableton, GA, United States of America

Shafiq A Khan